Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that plays a critical role in diverse cellular functions, such as DNA damage detection and repair, transcriptional regulation and cell death. Furthermore, PARP-1 has emerged as a key player in the pathogenesis of multiple inflammatory diseases and has become a promising target for the treatment of cardiovascular disorders, neurodegenerative diseases and cancer. An increasing body of evidence has linked alterations in the expression levels of PARP-1, enzymatic activity and presence of polymorphism to gastrointestinal malignancies, including oesophageal, gastric, pancreas, liver and colorectal cancers. PARP inhibition has been proposed as a valuable strategy for treating these gastrointestinal disorders. This paper summarises the most significant current literature on the involvement of PARP-1 in gastrointestinal cancer, focusing in particular on its role in the development and occurrence of tumours, providing information about clinical trials and exploring therapeutic possibilities.
['Martín-Guerrero|Sandra M|SM|', 'León|Josefa|J|', 'Quiles-Perez|Rosa|R|', 'Belmonte|Laura|L|', 'Martin-Oliva|David|D|', 'Ruiz-Extremera|Ángeles|Á|', 'Salmerón|Javier|J|', 'Muñoz-Gámez|José Antonio|JA|']
D000818:Animals D000970:Antineoplastic Agents D055808:Drug Discovery D005770:Gastrointestinal Neoplasms D041981:Gastrointestinal Tract D006801:Humans D058990:Molecular Targeted Therapy D000071137:Poly (ADP-Ribose) Polymerase-1 D000067856:Poly(ADP-ribose) Polymerase Inhibitors D020641:Polymorphism, Single Nucleotide
gastrointestinal cancer Biomarker PARP inhibitors carcinogenesis poly (ADP-ribose) polymerase-1
(PARP-1) synthetic lethality